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The objective of this review article is to explain the factors responsible 
for  damaged  mitochondria  and  its  association  with  Alzheimer’s  disease. 
Alzheimer’s disease (AD) is fairly produced by dysfunctional mitochondria 
that  are  alternatively  caused  by  excessive  reactive  oxygen  species  and 
mitochondrial  dynamic  imbalance.  In  the  pathogenesis  of  AD,  there  is 
important  role  of  many  factors  including  amyloid-beta  peptide  (A￿),  tau-
proteins, and mutations in presenilin-1. Additionally, mitochondrial-targeted 
antioxidants  have  also  been  explained  because  of  their  significance  to 
mitochondrial  alterations  in  AD.  Moreover,  alteration  in  mitochondrial 
dynamics  is  responsible  for  the  generation  of  segregated,  damaged 
mitochondria that are, later on, destroyed through mitochondrial autophagy in 
AD.  Finally,  various  novel  models  used for  studying  Alzheimer’s  disease, 
have been discussed.  
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INTRODUCTION 
Mitochondria, the important cytoplasmic organelles, have capability of modifying their 
shape  and  size  swiftly  in  accordance  with  their  needs.  Mitochondria  are  highly  dynamic 
organelles, which are continuously recycled (CHANG and REYNOLDS, 2006). In mammalians, the 
life span of mitochondria is different in different tissues, e.g. half-life of neuronal mitochondria 
is approximately 30 days (REDDY, 2008). This organelle consists of two lipid membranes i.e. the 
outer and inner mitochondrial membranes, separated by a matrix that houses tricarboxylic acid 
(TCA) and beta-oxidation. In contrast to highly porous outer membrane, the inner mitochondrial 632                                                                                                            GENETIKA, Vol. 46, No.2, 631-648, 2014 
membrane is an efficient barrier where electron transport chain (ETC) takes place (Figure 1) 
(REDDY, 2007).  
The functions of mitochondria include the regulation of intracellular calcium, arresting 
the free-radical, and ATP synthesis through OXPHOS within the inner mitochondrial membrane 
(WALLACE, 1999). As a byproduct of OXPHOS, free radicals are produced that are scavenged by 
antioxidant enzymes naturally present in adequate amounts in the mitochondria resulting in the 
protection of cells against oxidant-induced toxicities. However, imbalance between oxidants and 
antioxidant enzymes in certain cells (as in pyramidal neurons in cortex and hippocampus in 
Alzheimer’s disease (AD) brain) creates oxidative stress (REDDY, 2012a). The neuronal death 
due to senile plaques and neurofibrillary tangles (Table 1) in brain is termed as AD (REDDY et 
al., 2012a; ALZHEIMER et al., 1907). 
AD  is  medically  recognized  as  a  silent  neurodegenerative  disease  since  it  remains 
asymptomatic until its diagnosis (SAVVA et al., 2009). There are evidences that the oxidative 
stress in the central and peripheral nervous system (CECCHI et al., 2002; MOREIRA et al., 2007a) 
is  responsible  for  mitochondrial  dysfunction  (MD)  (BONDA  et  al.,  2010a).  It  results  in  the 
development of various neurodegenerative disorders (AVILA, 2010), including AD (ZHU et al., 
2013; MURTAZA et al., 2014) that can be categorized into two types: familial Alzheimer’s disease 
(FAD) and sporadic Alzheimer’s disease (SAD) (Table 2). FAD is found to be originated from 
mutations in at least one of the three genes recognized as amyloid precursor protein (APP) and 
presenilin-1 and -2(ps-1 and ps-2) (PRICE et al., 1998). The FAD involves the over-expression of 
beta-secretase (BACE1) protein that results in the excessive release  of amyloid-beta  peptide 
(A￿) (XIONG et al., 2007; TAMAGNO et al.,2005; GAO et al., 2013 ). The augmented production of 
A￿ elevates the levels of reactive oxygen species (ROS) (BELKACEMI and RAMASSAMY,2012; 
SANTOS et al.,2010), which induce the development of SAD involving tau accumulation (TAGA 
et al.,2011; BONDA et al.,2011; KOPEIKINA et al.,2011) and the enhanced A￿ formation under the 
effect of high levels of ROS (LEUNER et al.,2012). These cascade changes may initiate further 
MD, resulting in even higher levels of ROS (LAFERLA et al., 2007; SUN et al., 2013). These 
cyclic changes promote the neurodegeneration. 
 
 
Figure 1. Structure of mitochondria and electron transport of chain [1]  
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Table 1. Features of two abnormal structures, senile plaques and neurofibrillary tangles, present in the 
brain of AD patients [6] 
No.  Features  Senile plaques  Neurofibrillary tangles 
1  Name of main constituent  Amyloid-beta peptide (A￿)  Tau-protein 
2  Shape of main constituent  Thread-like aggregates  Microtubule-like structure 
3  Stage  of  appearance  in 
brain 
At last stage of AD disease  At last stage of AD disease 
4  Diagnostic approach  Autopsy  Autopsy 
Positron  emission 
tomography  imaging  using 
the Pittsburg compound B 
Positron  emission 
tomography  imaging  using 
18F-THK23 
. 
 
Table 2. Types of Alzheimer’s disease and their features [6] 
No.  Types of 
Alzheimer’s 
disease 
Features 
1 
Familial 
Alzheimer’s 
disease 
(FAD) 
Mutations in at least one of the three genes recognized as amyloid 
precursor protein (APP) and presenilin-1 and -2(ps-1 and ps-2) 
Over-expression of beta-secretase (BACE1) protein 
Excessive release of A￿ 
High levels of ROS 
Mitochondria dysfunction 
2 
Sporadic 
Alzheimer’s 
disease 
(SAD) 
Tau accumulation 
Enhanced A￿ formation 
Very high levels of ROS 
Mitochondria dysfunction 
 
Dysfunctioning of mitochondria 
Deregulation of oxidative phosphorylation proteins 
Mitochondia,  being  energy  generator  of  cell,  is  characterized  with  the  redox  potential 
gradient  in mitochondria that drives  the ETC through  mitochondrial complexes (CI to CIV) 
(OTERA et al., 2010). After accepting electron at CIV stage, oxygen is changed into water with 
simultaneous  release  of  energy.  This  energy  activates  ATP-synthase,  which  induces  the 
generation of ATP by the mitochondria (Figure 1). It is observed that normal and dysfunctional 
mitochondria produce ROS in low and high concentrations, respectively (MOREIRA et al., 2010). 
These ROS deteriorate the mitochondria through oxidation of the mitochondrial macromolecules 
including proteins, lipids, and mitochondrial DNA (mtDNA) (SCHMITT et al., 2012; HAUPTMANN 
et al., 2009; XIE et al., 2013). The ROS also play a role in the production of toxic substances 
such  as  hydroxynonenal  (HNE)  which  may  assist  the  aggregation  of  Tau  protein  into 
neurofibrillary  tangles  (SANTA-MAR´IA  et  al.,  2004).  In  dysfunctional  mitochondria,  there  is 634                                                                                                            GENETIKA, Vol. 46, No.2, 631-648, 2014 
progressively  diminished  brain  glucose  metabolism,  due  to  various  deregulating  molecules 
(Table 3) and reduced expression of either nuclear or mitochondrial genes responsible for the 
oxidative phosphorylation in the neocortex of AD patients (RHEIN et al.,2009; DAVID et al.,2005; 
ECKERT et  al.,2010;  CASPERSEN et al.,2005). This abnormality can be envisaged  by  positron 
emission tomography (CHANDRASEKARAN et al., 1996; CHANDRASEKARAN et al., 1997). 
                                                                                  
 
Table 3. The molecules and mitochondrial targets involved in deregulation of oxidative phosphorylation 
proteins in tricarboxylic acid cycle [6] 
 
No.  Target  Deregulating molecules 
1  Mitochondrial complex I  Tau 
2  Mitochondrial complex IV  A￿ 
3  Mitochondrial complex V  Tau 
 
 
In  Alzheimer’s  disease,  change  in  activity  of  some  enzymes  such  as  pyruvate 
dehydrogenase  and  ￿-ketoglutarate  dehydrogenase  has  been  observed.  Physiologically,  these 
enzymes are involved in the tricarboxylic acid cycle. Table 4 shows the effect of mitochondrial 
dysfunction on its enzyme activity (PERRY et al., 1980; GIBSON et al., 1988; SHEU et al., 1994) 
 
 
Table 4. Effect of mitochondrial dysfunction on its enzyme activity [6] 
 
No. 
Pathological change  Effect on enzymes 
Effects of reduced 
enzymatic activity 
1 
Changed level of enzymes 
involved in TCA cycle 
1. Reduced  activity  of 
pyruvate dehydrogenase 
2. Reduced  activity  of  ATP-
citrate lyase 
3. Reduced  activity  of 
acetoacetyl-CoA thiolase 
1. Reduced  production  of 
acetyl coenzyme A 
2. Cholinergic defects 
2 
Loss  of  ￿-ketoglutarate-
enriched cells 
Reduced  activity  of  ￿-
ketoglutarate dehydrogenase 
 
 
Imbalanced Mitochondrial Dynamics 
Healthy mitochondria normally undergo rapid and reversible fission and fusion processes in 
a programmed manner. This phenomenon, termed as mitochondrial dynamics, plays a vital role 
in  the  preservation  of  mitochondrial  structure  and  functions  such  as  metabolism,  ROS 
production,  and  apoptosis  regulation  (ZHU  et  al.,  2013;  WAHLSTER  et  al.,  2013).  Fission  is 
involved  in  the  recycling  of  mitophagy-mediated  destructed  mitochondria.  This  feature  is 
important for the correct assembly of mitochondrial complexes involved in ETC. Conversely,  
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fusion protects the mitochondria from autophagy-provoked demolition. This protective process 
also  manages  the  correct  distribution  of  mitochondrial  elements  including  lipid  bilayer 
membranes,  oxidative  phosphorylation  complexes,  and  mtDNA.  A  very  delicate  balance 
between fission and fusion is needed for proper mitochondrial distribution in the cell, especially 
in neurons (DETMER and Chan, 2007; ZHAO et al., 2011; LUO et al., 2013) and is executed under 
the  control  of  numerous  mitochondrial  proteins,  e.g.  outer  mitochondrial  membrane  (OMM) 
proteins. Various types and activities of OMM proteins involved in mitochondrial dynamics are 
presented in Table 5. 
 
Table 5. Outer mitochondrial membrane (OMM) proteins and their activities [6] 
No. 
Fission  Fusion 
Name  Function  Name  Function 
1 
GTPase  dynamin-like 
protein  1  (DLP1),  or 
dynamin-related  protein, 
(Drp1)  imported  from 
cytosol 
  GTPases-related 
Mitofusin 1 and 2 
(Mfn1 and Mfn2) 
Outer  membrane 
fusion 
2 
Fis1  Regulatory 
functions 
Optic  atrophy 
(Opa1) 
Inner  membrane 
fusion,  cristae 
formation,  and 
mtDNA inheritance) 
3 
Mitochondrial Fission factor 
(Mff) 
Influx  of 
DLP1 
Mitochondrial 
elongation  factor 
1 (MIEF1) 
Inactivation of DLP1 
 
 
As evident from studies conducted in neurodegenerative disorder models, mitochondrial 
dynamics  imbalance  may  results  in  mitochondrial  dysfunction  (WANG  et  al.,  2008a).  This 
alteration, along with synaptic degeneration, is considered an initial stage in AD (REDDY et al., 
2012b; ZHAO et al., 2013). In AD, fission is a dominant process over fusion in the presence of 
damaged  mitochondria  in  neurons  (BONDA  et  al.,  2010b;  OETTINGHAUS  et  al.,  2012)  or 
fibroblasts (ZHU et al., 2013, WANG et al., 2013). These cells also exhibit altered mitochondria 
distribution, particularly accumulated into perinuclear region (WANG et al., 2009). Twisted, long 
mitochondria are seen in fibroblasts from sporadic AD patients, this alteration is attributable to 
differences in the expression prototype of proteins engaged in dynamics, revealing diminished 
DLP1 (ZHU et  al.,  2013;  WANG  et al., 2008a). In AD brain,  overall  size  of mitochondria is 
increased  due  to  its  fragmentation  and  thickening  in  damaged  neurons,  which  suggests 
mitochondrial  dynamics  alterations  (WANG  et  al.,  2008b),  as  confirmed  from  ADDLs  (A￿-
derived diffusible ligands)-treated primary hippocampal neurons (WANG et al., 2009). These cells 
also exhibit the diminished levels of OPA1, Mfn1, and Mfn2 as well as elevated levels of Fis1 in 
AD. About the alteration in DLP1 level in neurons and fibroblasts, researchers have narrated 
mixed opinions (WANG et al., 2008b; BOSSY et al., 2010: MANCZAK et al., 2011). Its import from 
cytosol to mitochondrial membrane to intervene fission events is dependent on posttranslational 
modifications  (ZHU et  al.,2013),  this explanation  may  account  for  higher  levels  of  DLP1 in 636                                                                                                            GENETIKA, Vol. 46, No.2, 631-648, 2014 
mitochondrial  fraction  (WANG  et  al.,2009)  in  addition  to  elevated  levels  of  Ser616 
phosphorylation and S-nitrosylation in AD brains (CHO et al.,2009). Moreover, an increase in 
abnormal interaction of DLP1 with A￿ monomers and oligomers with the advancement of AD 
might be a likely reason of abnormal mitochondrial dynamics and synaptic failure (MANCZAK et 
al., 2011). 
The  mitochondrial  fission  and  fusion  processes  can  be  coupled  with  its  transport.  This 
phenomenon is evident from a study that elaborates the interaction of Mfn2 with two adaptor 
proteins, Miro and Milton (MISKO et al., 2010; ZHANG et al., 2013). This outcome reveals that 
mitochondrial mobility is also altered in AD; it causes the mitochondrial reduction in neuritis 
(ZHU  et  al.,  2013).  Another  study  exhibits  the impairment  in  mitochondrial  mobility  by  A￿ 
(VEGA et al., 2013) and ADDL (VEGA et al., 2013) , respectively. In short, mtDNA damage, 
elevated oxidative stress, abnormal cristae, and synaptic failure are possible consequences of 
altered mitochondrial dynamics (ZHU et al., 2013; CHEN et al., 2013). 
 
Role of Amyloid Beta, Presenilin, and Tau in Mitochondrial Damage and Alzheimer’s disease 
In FAD, the built up of APP and A￿ in the protein import channels (translocase of the outer 
mitochondrial membrane 40, TOM40, and translocase of the inner mitochondrial membrane 23, 
TIM23) of mitochondrial membranes of human AD brains causes the structural and functional 
damage  by  producing  elevated  levels  of  ROS  and  oxidative  stress  (SCHMITT  et  al.,  2012; 
BELKACEMI and  RAMASSAMY, 2012;  BUTTERFIELD, 2002;  PAGANI and  ECKERT, 2011; DEVI et 
al.,2006).  It  is  associated  with  diminished  cytochrome  ￿  oxidase  activity,  possibly  due  to 
decreased entrance  of  cytochrome  ￿  oxidase  subunits  IV and  Vb  proteins  into  mitochondria 
(BELKACEMI  and  RAMASSAMY,  2012).  In  addition,  the  inactivation  of  presequence  protease 
(PreP) by A￿-induced oxidative stress also results in the aggregation of A￿ in mitochondrial 
matrix leading to elevated levels of ROS (ALIKHANI et al., 2009). Moreover, A￿ interact with 
phosphorylated Tau in VDAC1 (voltage-dependent anion channel 1) in AD brains of human and 
mice  leading  to  blockage  of  mitochondrial  pores,  and  eventually  failure  of  mitochondria 
(MANCZAK and REDDY, 2012; XING et al., 2013). Another study states that cyclophilin D is an 
important constituent of the mitochondrial permeability transition pore (mPTP). On interaction 
with mitochondrial A￿, the opening of the mPTP occurs. Simultaneously, cyclophilin D initiates 
the generation of free radicals, promote the synaptic failure and induces the apoptosis (DU et al., 
2008;  XING  et  al.,  2012).  Moreover,  cytoskeletal  abnormalities  may  also  appear  due  to  the 
accumulation of A￿ (KANG et al., 2011). On interaction with A￿ oligomers, integrins inhibit the 
cofilin-mediated actin dynamics that is linked with enhanced ROS generation and diminished 
mitochondrial  potential.  In  response  to  oxidative  stress,  the  translocation  of  cofilin  to  the 
mitochondria occurs leading to induction of swelling as well release of cytochrome ￿. Finally, 
the opening of mPTP occurs followed by the induction of apoptosis. 
In  AD  brains  of  human  and  transgenic mice,  the  upregulation  of  mitochondrial  protein 
ABAD  (A￿-binding  alcohol  dehydrogenase)  is  observed  (LUSTBADER  et  al.,  2004).  The 
interaction  between A￿ and ABAD results in the formation  of a complex, which averts the 
binding  of  NAD
+  (nicotinamide  adenine  dinucleotide)  to  ABAD.  Because  of  this  situation, 
alteration of mitochondrial membrane permeability as well reduction in the respiratory enzymes 
activities  occurs  causing  increased  levels  of  ROS.  In  addition,  DLP1  is  nitrosylated  by  A￿ 
leading to nitrosative stresss that produces mitochondrial fission in neurons (CHO et al., 2009).  
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High molecular weight, ps-￿-secretase complex is obtained because of association between 
presenilins  1/2  (ps-1/ps-2)  and  nicastrin/APH-1/PEN-2  (ANKARCRONA  and  HULTENBY,  2002; 
HANSSON et al., 2004) in mitochondria associated endoplasmic reticulum membranes (MAM) 
which are engaged in mitochondrial activity and  dynamics (AREA-GOMEZ et al., 2012). This 
complex is capable of modifying mitochondrial membrane potential (BEHBAHANI et al., 2006). 
Because  of  mutations  in  presenilins,  impaired  mitochondrial  function,  elevated  levels  of 
mitochondrial  ROS,  oxidative  damage,  and  mitochondrial  apoptosis  have  been  observed.  In 
addition, intra-membrane cleavage of APP produces A￿. 
Tau-mediated axonal translocation of mitochondria is crucial for synaptic activity (TRINCZEK et 
al.,  1999),  which  is  adversely  affected  by  hyperphosphorylation  of  Tau  resulting  in 
neurodegeneration due to energy deficiency and oxidative stress at the synapses (STAMER et al., 
2002; IIJIMA-ANDO et al., 2012). The study of brain proteins obtained from P301L mutant human 
tau  transgenic  mice  exhibited the  deregulation  of  mitochondrial  respiratory  chain  complexes 
such  as  reduced  complex  I  activity,  a  damaged  mitochondrial  respiratory  energistics 
accompanied  by  decreased  ATP  levels,  ROS  accumulation,  and  increased  susceptibility  to 
oxidative  stress  (DAVID  et  al.,2005;  SCHULZ  et  al.,2012).  Moreover,  annonacin-mediated 
inhibition of complex I resulting in apoptosis is also reported (ESCOBAR-KHOHDIKER et al.,2007) 
When  hyperpho-sphorylated  Tau  interact  with  mitocho-ndrial  fission  protein  (DLP-1),  an 
alteration in mitochondrial dynamics is observed accompanied by mitochondrial dysfunction and 
apoptosis  (MANCZAK  et  al.,2011;  DUBOFF  et  al.,2012).  As  far  as  morphology  is  concerned, 
tangled, filamentous mitochondria are observed from studies conducted on Drosophila (R406W) 
and mouse neurons (P301L). 
 
Therapeutic strategies for AD 
 
Usage of Mitochondria-Targeted Antioxidants 
Considering mitochondrial dysfunction and oxidative stress as some etiologies of AD, many 
antioxidant therapies, including vitamin E, huperzine A, curcumin, Gingo biloba, and melatonin, 
have been tested (CONTE et al., 2004; YANG et al., 2005; STACKMAN et al., 2003; MATSUBARA et 
al.,2003)for  their  efficiency  to  improve  mitochondrial  function  and  cognitive  behavior  by 
decreasing A￿ levels in animal models of AD. In clinical trials, non-significant effect of these 
antioxidants in cognitive function is observed, which is attributable to very severe disease state 
or ineffective supply of blood through blood-brain barrier (MISKO et al., 2010). In this regard, 
mitochondria-targeted antioxidants including choline esters of glutathione, N-acetyl-l-cysteine 
(SHEU et al., 2006), triphenylphosphonium-based molecules (MitoQ, MitoVitE, Mito-￿-lipoic 
acid, and MitoPBN) (MURPHY and SMITH, 2007), and peptide-based antioxidants (Szeto-Schiller 
or  SS  peptides  including  SS31,  SS02,  SS19,  and  SS20)  (SZETO,  2006)  have  also  been 
investigated  (Table  6).  Accordingly,  triphenylphosphonium-based  molecules are  the  resultant 
products when hydrophobic triphenylphosphonium cation reacts with ubiquinol, ￿-tocopherol, 
￿-lipoic acid, and ￿-phenyl N-tert-butylnitrone, respectively. Due to cationic nature, tremendous 
built up of this group of antioxidants in mitochondria promisingly protects the mitochondria 
against oxidative stress (MURPHY and SMITH, 2007). 
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Table 6. Various classes of mitochondria-targeted antioxidants and their examples 
No.  Classes  Examples 
1 
Triphenylphosphonium-based 
molecules 
MitoQ, MitoVitE, Mito-￿-lipoic acid, MitoPBN, 
and SKQ1 
2  Peptide-based antioxidants  SS31, SS02, SS19, and SS20 
 
MitoQ and SS31 have been tested for in vitro antioxidant study and found effective for 
prevention  of  hazardous  effects  (as  explained  above)  of  A￿  in  mouse  cell  models  of  AD 
(neuroblastoma cells, N2a cells, and A￿ precursor protein transgenic mouse cells, Tg2576 cell 
line) (CALKINS et al.,2011; MANCZAK et al.,2010). The mode of antioxidant activity of MitoQ 
and SS31 is related to its potential to decrease in cyclophilin D expression, while alone SS31 
mitigate the oligomeric A￿ effects by restoring mitochondrial mobility and alone MitoQ averts 
the cognitive failure in 3xTg-AD mice by scavenging the free radicals (MCMANUS et al., 2011). 
One  more  example  of  mitochondria-targeted  antioxidants  is  SKQ1 
(plastoquinonyldecyltriphenylphosphonium)  that  is  a  membrane-penetrating  cationic  specie 
having capability of accumulation in the inner mitochondrial membrane (SKULACHEV, 2012). 
Because  of  ROS  scavenging  activity,  SKQ1  has  a  potential  feature  of  anti-aging  in  rats 
(STEFANOVA et al., 2010). 
Due to the tyrosine or dimethyltyrosine (Dmt) moiety, SS peptides are potential scavengers 
of H2O2 and ONOO
– as well inhibitor of lipid peroxidation (SZETO, 2006). The ROS scavenging 
activity of Dmt is demonstrated to be higher than that of tyrosine. 
An in vivo study compared the APP mice with APP transgenic mice loaded with human 
mitochondria-targeted catalase (MCAT) gene and found that life of later mice was 5 months 
more than the former mice (MAO et al.,2012). The increase in life-span of transgenic mouse 
could be due to the reduction in the levels of BACE1 and A￿ levels (40 and 42). 
All these results elaborate that mitochondria-targeted antioxidants may be a successful remedy 
for the treatment of patients suffering from AD. 
 
Autophagy of Damaged Mitochondria 
Physiologically, the recycling process in which lysosomes degrade the macromolecules and 
cellular  organelles  is  called  autophagy,  whereas  the  autophagy  of  mitochondria,  termed  as 
mitophagy,  involves  the  engulfment  of  dysfunctional  mitochondria  into  autophagosomes 
followed  by  their  lysosomal  degradation.  In  AD,  alteration  in  mitochondrial  dynamics  is 
responsible for the generation of segregated, damaged mitochondria that are, later on, destroyed 
through mitochondrial autophagy (MOREIRA et al., 2007b). However, it is still under-discussion 
whether mitophagy is protective process or pathologic. 
The proposed mode of mitochondrial autophagy starts with mitochondrial damage followed by a 
series of activities, i.e. E3 ubiquitin ligase Parkin-induced kinase 1 stimulates Parkin-mediated 
ubiquitination  to  recruit  autophagy  adapter proteins  (p62).  The  interaction  of  p62  with  LC3 
provokes  the  autophagosomal  engulfment.  Accordingly,  there  are  evidences  that  many 
mitochondrial proteins (e.g. VDAC1 and mitofusins) may inhibit mitochondrial fusion events 
resulting in the segregation of damaged mitochondria (GEGG et al., 2010; Burns et al., 2009). 
Moreover, all factors affecting mitochondrial dynamics in AD (as discussed above) may initiate 
mitochondrial damage and ROS buildup.  
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There is a strong association between autophagy and the aggregation of AD-related protein 
such  as A￿  and  Tau  (NIXON  et  al.,  2005)  in  neuronal  cells.  In neurons  of  AD  patients,  an 
increased  number  of  mitochondria-containing  autophagic  vesicles  has  been  reported  that 
suggests a mitophagy alteration (MOREIRA et al., 2007c). Another study elaborates that the cortex 
of  AD  brains  contains  a  reduced  level  of  Parkin,  which  is  a  protein  target  of  mitophagy 
(MOREIRA et al., 2007c). Beclin 1 is another protein target of mitophagy. In the diseased part of 
AD brain of an APP transgenic mouse model, reduced level of Beclin 1 is found at early stage of 
disease (PICKFORD et al., 2008; KHANDELWAL et al., 2011). Due to which an increase in the 
intra-  and  extra-cellular  level  of  A￿  occurs  resulting  in  neurodegeneration,  it  highlights  the 
relationship  bebtween  autophagy  and  AD-associated  pathology.  In  addition,  the  relationship 
between FAD and autophagy has also been reported in a study, which shows that autophagy is 
damaged  by  Alzheimer-related  ps-1  mutations  since  autophagy  requires  functional  Ps-1  for 
lysosomal  activity  (LEE  et  al.,  2010).  Therefore,  mitophagy  can  be  impaired  through  ps-1 
mutations, and thus ultimately influences mitochondrial activity. Alternatively, the pathogenic 
role of autophagy in AD development has been proposed. The authors reported that autophagic 
vesicles are involved in the production and abnormal storage of A￿ in damaged neuronal cells of 
the AD brain (YU et al., 2004). 
Moreover, numerous other molecules, such as rapamycin (CACCAMO et al., 2010; SPILMAN 
et al., 2010), cystatin B (YANG et al., 2011), trehalose (SCHAEFFER et al., 2012), scyllo-Inositol 
(LAI  and  MCLAURIN,  2012),  and  latrepirdine  (STEELE  and  GANDY,  2013),  have  also  been 
investigated to explore their potential to induce autophagy as a therapeutic approach in the AD 
animal models. 
Alzheimer’s disease modeling 
In comparison to image analysis, living cells should preferably be employed for the correct 
study  of  mitochondrial  functions  since  mitochondria  are  extremely  dynamic  organelles  that 
perform  numerous  cellular  functions.  Thus,  novel  models  for  studying  AD  include  animal 
models, patient-derived non-neuronal cells, and postmortem investigation of the patient’s brain. 
In this context, fibroblasts, the differentiated cells derived from adult patients, can be used to 
produce stem cells through retro-differentiation (TAKAHASHI and YAMANAKA, 2006; TAKAHASHI 
et al., 2007; YU et al., 2007); however, such results are needed to be adjusted/extrapolated to 
generate neuron-associated data, since fibroblasts and neurons are different from each other in 
many respects such as energy requirements, morphology, and gene/protein expression pattern 
(CHIN et al., 2009; POLOULIAKH, 2013). Currently, FAD animal models are generally available to 
study mitochondrial functions; however, SAD models should also be explored accordingly. 
Moreover,  there  are  evidences  that  cell  encoding  can  be  reversed,  since  the  induced 
pluripotent stem cells (iPS) have been generated by four transcriptions factors, Oct3/4, Sox2, c-
Myc, and Klf4 (TAKAHASHI and YAMANAKA,2006), which can be substituted by small molecules 
(HUANGFU et al.,2008; ICHIDA et al.,2009; LI et al.,2011) or microRNAs (JUDSON et al.,2009; 
LIN et al.,2011; ANOKYE-DANSO et al.,2011) for transcription factors. For studying AD, these 
iPS have been employed to generate neurons such as the usage of presenilin-associated FAD 
patient’s fibroblasts and APP duplication associated AD fibroblasts for increased production of 
A￿42 and A￿40, respectively (YAGI et al.,2011; ISRAEL et al.,2012). In more advance studies, 
functional neurons (induced neurons, iN) have been directly obtained from fibroblast e.g. neural 
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have been derived from fibroblast. These conversions have been mediated by three transcription 
factors, Ascl1, Brn2 (also called Pou3f2), and Myt1l (THEIR et al., 2012; VIERBUCHEN et al., 
2010) or one microRNA and two transcription factors (PANG et al., 2011; YOO et al., 2011). A 
recent  study  has  reported  the  obtention  of  reprogrammed/functional  neurons  from  human 
fibroblasts suffering from AD (AMBASUDHAN et al., 2011). 
From  above  discussion,  it  is  clear  that  the  survival  and  differentiation  of  neurons  is 
dependent on mitochondrial function. There, it is very crucial that the integrity of mtDNA should 
be maintained during differentiation of neuronal stem cells, since oxidative stress and protein 
levels (such as DLP1 and prohibitin) in mitochondria (QIANG et al.,2011) may damage mtDNA 
integrity  and  thus  reprogramming  from  fibroblasts  to  neurons  (ZHOU  et  al.,2012;  WANG  et 
al.,2010). 
CONCLUSION 
For  studying  neurodegenerative  disorders  such  as  Alzheimer’s  disease,  various  models 
including  iPS,  iN,  or  iNSC  have  increasingly  been  used,  however  these  models,  especially 
human cellular models, should also be employed to study mitochondrial functions. In order to 
execute such type of approach, future research can be focused on high through-put protocols 
such as fastening the neuron generation rate. 
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Izvod 
 
 
Alchajmerova  bolet  (AD)  je  u  velikom  stepenu  prouzrovana  disfunkcijama  mitohondrijama  
alternativno  izazvanim  ekcesivno  reaktivnim  vrstama  kiseonika  i  inbalansa  dinamike 
mitohondrija.  U  patogenezi  AD  važna  je  uloga  mnogih  faktora  koji  uključuju  amiloid-beta 
peptide  (A￿).  Tau  –  protein  i  mutacije  u  presenilinu-1.  Dodatno,  mitohondrije  –  ciljani 
antioksidanti su objašnjeni zbog njihovog značaja za izmenu mitohondrija u AD. Uz to, promena 
u dinamici mitohondrija je odgovorna za izazivanje segregacije oštećenih mitohondrija koje se 
kasnije uništavaju mitohondrijalnim autofagama kod AD. Diskutovani su različiti novi modeli 
korišćeni u ispitivanjima Alchajmerove bolesti.  
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